EGRX News and Press, Eagle Pharmaceuticals Inc. From 03/07/22

Eagle Pharmaceuticals press release (NASDAQ:EGRX): Q4 Non-GAAP EPS of $0.85 misses by $0.09. Revenue of $42.32M (-15.2% Y/Y) misses by $8.76M. “With two important launches in early 2022, Eagle is off to a great start. The initial impressive revenue generated from vasopressin and PEMFEX...

Q4 2021 net loss was $(0.48) per basic and diluted share and adjusted non-GAAP net income* was $0.87 per basic and $0.85 per diluted share FY 2021 net loss was $(0.66) per basic and diluted share and adjusted non-GAAP net income* was $2.64 per basic and $2.59 per diluted share Ear...

Eagle Pharmaceuticals (NASDAQ:EGRX) is scheduled to announce Q4 earnings results on Monday, March 7th, before market open. The consensus EPS Estimate is $0.94 (-2.1% Y/Y) and the consensus Revenue Estimate is $51.08M (+2.4% Y/Y). Over the last 2 years, EGRX has beaten EPS estimates 63% of the...

CIEN, EGRX, NIU, VET For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open

Endo International (NASDAQ:ENDP) was stripped of its legal defenses in an upcoming trial in Tennessee over the company’s role in the opioid crisis, Bloomberg reported on Tuesday. The decision taken by Judge Jonathan Lee Young of Tennessee Circuit Court was due to Endo&#x...

WOODCLIFF LAKE, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 fourth quarter and full year financial results on Monday, March 7, 2022, before th...

Eagle Pharmaceuticals (NASDAQ:EGRX) announces the commercial availability of its novel product Pemfexy (pemetrexed for injection). A branded alternative to Eli Lilly's Alimta, Eagle’s PEMFEXY is a ready-to-use liquid with a unique J-code approved to treat nonsquamous non-smal...

-- Sales of PEMFEXY (pemetrexed for injection) commence today -- -- ALIMTA ® U.S. market totaled $1.2 billion for the twelve months ended September 30, 2021 -- -- Launch expected to drive significant revenue growth in 2022 -- Eagle Pharmaceuticals, Inc. (Nas...

-- Anticipate Landiolol to become market leader in this drug class -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group, (“AOP Healthȁ...

-- Shipment of vasopressin, a generic alternative to Vasostrict ® , commences today, with 180 days of marketing exclusivity -- -- Product launch expected to drive significant revenue growth in 2022 -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle...